La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Opthea Gestion

Gestion contrôle des critères 0/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Fred Guerard

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	1.2yrs
Durée moyenne du mandat des membres du conseil d'administration	2.4yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Fred Guerard (51 yo)

less than a year

Titularisation

Dr. Frederic Guerard, Pharm. D. M.S. also known as Fred, is Chief Executive Officer of Opthea Limited from October 27, 2023. He has been Independent Director at Lenz Therapeutics, Inc. since 2021.He is a...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Megan Baldwin	Founder	no data	US$1.57m	0.016% $ 114.2k
Judith Robertson	Chief Commercial Officer	2.7yrs	US$856.83k	pas de données
Karen Adams	VP of Finance & Company Secretary	3.3yrs	US$507.60k	pas de données
Frederic Guerard	Chief Executive Officer	less than a year	pas de données	pas de données
Peter Lang	Chief Financial Officer	less than a year	pas de données	pas de données
Sarika Gulhar	Executive Director of Human Resources	1.7yrs	pas de données	pas de données
Michael Gerometta	Head of Chemistry	15.8yrs	US$197.04k	pas de données
Bruno Gagnon	Senior Vice President of Global Clinical Operations	2yrs	pas de données	pas de données
Kenneth Sall	Chief Medical Officer	1.2yrs	pas de données	pas de données
Fang Li	Senior Vice President of Regulatory Affairs	less than a year	pas de données	pas de données
Julie Clark	Senior Vice President of Clinical Development	less than a year	pas de données	pas de données
Arshad Khanani	Chief Medical Advisor	less than a year	pas de données	pas de données

1.2yrs

Durée moyenne de l'emploi

52yo

Âge moyen

Gestion expérimentée: L'équipe de direction de OPT n'est pas considérée comme expérimentée (ancienneté moyenne 1.1 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Megan Baldwin	Founder	no data	US$1.57m	0.016% $ 114.2k
Jeremy Levin	Chairperson	3.9yrs	US$425.47k	0.0026% $ 18.4k
Jason Slakter	Member of Clinical Advisory Board	no data	pas de données	pas de données
Quinton Oswald	Independence Non-Executive Director	2.4yrs	US$202.36k	pas de données
Julia Haller	Independent Non-Executive Director	3.3yrs	US$327.41k	pas de données
Lawrence Gozlan	Independent Non-Executive Director	4.2yrs	US$724.31k	0.15% $ 1.1m
Sujal Shah	Non-Executive Director	less than a year	pas de données	pas de données
Anshul Thakral	Non-Executive Director	1.3yrs	US$3.16k	pas de données
Charles Wykoff	Member of Clinical Advisory Board	no data	pas de données	pas de données
Susan Orr	Independent Non-Executive Director	2.4yrs	US$206.20k	pas de données
Andrew Chang	Member of Medical Advisory Board	less than a year	pas de données	pas de données
Tim Jackson	Member of Clinical Advisory Board	no data	pas de données	pas de données

2.4yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de OPT ne sont pas considérés comme expérimentés (ancienneté moyenne 2.3 ans), ce qui suggère un nouveau conseil d'administration.

Opthea Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Opthea Limited Announces Board Appointments

Less than half of directors are independent

Opthea Limited Announces Board Changes

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Recent updates

Full year 2024 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2027

New minor risk - Profitability

Consensus revenue estimates decrease by 10%, EPS upgraded

Price target decreased by 10% to AU$0.79

Opthea Limited Announces Board Appointments

Opthea Limited has completed a Follow-on Equity Offering in the amount of AUD 227.314307 million.

Forecast to breakeven in 2027

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

Price target increased by 14% to AU$0.90

Consensus revenue estimates decrease by 96%, EPS upgraded

New major risk - Financial position

Consensus revenue estimates increase by 13%

New minor risk - Profitability

Consensus revenue estimates decrease by 14%

Less than half of directors are independent

Consensus EPS estimates fall by 11%

Opthea Limited Announces Board Changes

Consensus revenue estimates fall by 94%

Consensus revenue estimates decrease by 14%, EPS upgraded

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Consensus revenue estimates decrease by 94%

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 94%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 9.0% to AU$1.55

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

Consensus revenue estimates increase by 12%

Consensus EPS estimates upgraded to US$0.25 loss

Consensus EPS estimates fall by 44%

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Consensus revenue estimates increase by 12%

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$173k worth of stock.

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Consensus forecasts updated

Full year 2022 earnings: EPS and revenues miss analyst expectations

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Consensus forecasts updated

Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate

Price target decreased to AU$2.95

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020)

Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada